Sanofi Hopes BioNTech Pact Can Help Reboot Cancer Prospects
This article was originally published in Scrip
Executive Summary
Working hard to re-boot its cancer strategy, Sanofi SA of France has entered its latest multi-year collaboration in the field, this time with German biotech BioNTech AG to discover and develop up to five immunotherapies, each consisting of a mixture of synthetic messenger RNAs (mRNAs).
You may also be interested in...
Sanofi Takes €80M BioNTech Stake & Extends 2015 Deal
BioNTech gets an €80m boost to its reserves as Sanofi takes equity stake as partners extend 2015 deal and advance an mRNA-based cancer immunotherapy into clinic against multiple solid tumors
Genentech, BioNTech Pact Aims To Make Targeted Cancer Vaccines
Genentech will tap expertise of privately-held BioNTech in a collaboration aimed at developing individually tailored vaccines for use against a broad range of cancers, which the duo says offers “a new treatment paradigm” for oncology.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.